## AB-PK537 BARK1-Y356 Antibody

Phosphosite-specific polyclonal antibody for monitoring the phosphorylation of human protein-serine/threonine kinase BARK1 (GRK2, ADRBK1)



Address: 8755 Ash Street, Suite 1 Vancouver, British Columbia, Canada V6P 6T3

Email: info@kinexus.ca Phone: 604-323-2547

Target Protein	
Name Long:	Beta-adrenergic receptor kinase 1
Alias:	ADRBK1; Adrenergic, beta, receptor kinase 1; ARBK1; BARK; BARK1; Beta- adrenergic receptor kinase 1; Beta-ARK-1; EC 2.7.11.15; FLJ16718; G- protein coupled receptor kinase 2; Kinase GRK2
UniProt ID:	P25098
Sequence Predicted Mass (KDa):	79.574 (689 AA; P25098)
Observed SDS-PAGE Mass (KDa):	78-85
Immunogen	
Antibody Immunogen Source:	Human BARK1 (GRK2, ADRBK1) sequence peptide Cat. No.: PE-04ACJ85
Antibody Immunogen Sequence:	THG(pY)MAP(bA)C (bA) = beta-alanine
Location in Target:	Corresponds to amino acid residues T353 to P359; In the protein kinase catalytic domain activation T loop region between subdomains VII and VIII.
Peptide Type:	For phosphosite-specific recognition of target.
Target Phosphosite:	Tyr-356
Production Antibody Host Species:	Rabbit
Antibody Type:	Polyclonal
Antibody Ig Isotype Clone Lot:	Immunoglobulin G
	The immunizing peptide was produced by solid phase synthesis on a multipep
Production Method:	peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. This antibody was also subject to negative purification over phosphotyrosine-agarose.
	peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. This antibody was also subject to negative purification
Production Method: Antibody Amount: Antibody Concentration:	peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. This antibody was also subject to negative purification over phosphotyrosine-agarose.
Antibody Amount:	<ul> <li>peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. This antibody was also subject to negative purification over phosphotyrosine-agarose.</li> <li>25 μg</li> </ul>
Antibody Amount: Antibody Concentration:	<ul> <li>peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from each animal was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris. This antibody was also subject to negative purification over phosphotyrosine-agarose.</li> <li>25 μg</li> <li>0.5 mg/ml</li> </ul>

## AB-PK537 BARK1-Y356 Antibody

all and an a



Address: 8755 Ash Street, Suite 1 Vancouver, British Columbia, Canada V6P 6T3

Email: info@kinexus.ca Phone: 604-323-2547

Applications	
Product Use:	Western blotting   Antibody microarrays
Antibody Dilution Recommended:	2 µg/ml for immunoblotting
Antibody Species Reactivity:	Human, mouse, rat and many other vertebrates; Phosphosite is highly conserved in diverse species
Antibody Positive Controls:	Very strong immunoreactivity with immunogen peptide on dot blots.
Detection by Immunoblotting in Cell/Tissue Lysates:	Strong immunoreactivity of a target-sized protein by Western blotting in FBS- treated Jurkat cells and weakly in HeLa cells.
<b>Overall Antibody Specificity:</b>	Very high selectivity
Antibody Cross Reactivities:	No medium to strong cross-reactivities with other proteins in Jurkat cells, HeLa cells, and sea star oocytes.

This product is for in vitro research use only and is not intended for use in humans or animals.